Rahul V. Parghane

Clinical utility of ¹⁷⁷Lu‐DOTATATE PRRT in somatostatin receptor‐positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity

Rahul V. Parghane, Chinna Naik, Sanjay Talole et al. · Head & Neck · 2019 · 66 citations

Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort

Sonam Suman, Rahul V. Parghane, Amit Joshi et al. · British Journal of Radiology · 2019 · 57 citations · Full text

Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Rahul V. Parghane, Sanjay Talole, Kumar Prabhash et al. · Clinical Nuclear Medicine · 2017 · 55 citations

Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant ¹⁷⁷Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors

Rahul V. Parghane, Manish Bhandare, Vikram Chaudhari et al. · Journal of Nuclear Medicine · 2021 · 47 citations · Full text

Long-term outcome of “Sandwich” chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease

Rahul V. Parghane, Vikas Ostwal, Anant Ramaswamy et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 44 citations

Surgical Oncology, “ Sandwich, Novel Treatment Strategy +8